Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.

Related Videos

Related Content

Advertisement

February 14th 2025

ACS’ Dahut on Finding Cancer Before It Starts, and Funding Researchers as They Start

Mary Caffrey

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in prostate cancer.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

February 14th 2025

TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status

Mary Caffrey

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic castration-resistant prostate cancer (mCRPC).

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

February 11th 2025

Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025

Mary Caffrey

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

February 11th 2025

Changes in Tumor Size Track Advanced RCC Outcomes, Analyses From CLEAR Show

Interview by Mary Caffrey

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary Cancers Symposium later this week in San Francisco, California.

Related Content

Advertisement

February 14th 2025

ACS’ Dahut on Finding Cancer Before It Starts, and Funding Researchers as They Start

Mary Caffrey

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in prostate cancer.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

February 14th 2025

TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status

Mary Caffrey

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic castration-resistant prostate cancer (mCRPC).

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

February 11th 2025

Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025

Mary Caffrey

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

February 11th 2025

Changes in Tumor Size Track Advanced RCC Outcomes, Analyses From CLEAR Show

Interview by Mary Caffrey

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary Cancers Symposium later this week in San Francisco, California.